Jim Simons
RAPP

Jim Simons’s Rapport Therapeutics RAPP Stock Holding History

Jim Simons’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$304K Sell
9,700
-109,114
-92% -$3.07M ﹤0.01% 2787
2025
Q4 		$3.6M Buy
118,814
+83,514
+237% +$2.31M 0.01% 1522
2025
Q3 		$1.05M Buy
35,300
+19,700
+126% +$351K ﹤0.01% 2460
2025
Q2 		$177K Buy
+15,600
New +$166K ﹤0.01% 3193

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Jim Simons's RAPP Position: Q1 2026 in Review

Jim Simons reduced its Rapport Therapeutics (RAPP) stake by 92% in Q1 2026, selling an estimated $3.07M and leaving 9,700 shares worth $304K. The position accounts for ﹤0.01% of the portfolio, ranked #2787.

Jim Simons first reported a position in RAPP in Q2 2025 and has held it in 4 quarters since. The position peaked at $3.6M in Q4 2025. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • Jim Simons held 9,700 shares of Rapport Therapeutics worth $304K as of Q1 2026.
  • Jim Simons sold 109,114 Rapport Therapeutics shares in Q1 2026, an estimated $3.07M.
  • Rapport Therapeutics made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #2787 holding.
  • Jim Simons first reported a position in Rapport Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Jim Simons's Rapport Therapeutics position peaked at $3.6M in Q4 2025.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.